第三条 公司总经理主持公司日常业务经营和管理工作，并受董事会委托组 织实施董事会会议决议，对董事会负责。联席总经理根据公司总经理工作细则及 总经理办公会确定的职责分工，协助总经理开展工作。 第四条 总经理的工作应贯彻诚信、勤勉、守法、高效的原则。 第二章总经理职责与分工 大参林医药集团股份有限公司 总经理工作细则 第一章总则 第一条 为更好地管理大参林医药集团股份有限公司（以下简称"公司"） 生产经营工作，促进公司经营管理的制度化、规范化、科学化，确保公司重大生 产经营决策的正确性、合理性，提高民主决策、科学决策水平，以使公司的生产 经营高效有序进行，根据《中华人民共和国公司法》等法律、行政法规、部门规 章、规范性文件和《大参林医药集团股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，并结合公司的实际情况，制定本细则。 第二条 公司设总经理一名，由公司董事会聘任或解聘；公司可以设联席总 经理一名，由公司董事会聘任或解聘；公司设副总经理若干名，由总经理提名， 董事会聘任或解聘；公司设财务总监一名，由总经理提名，董事会聘任或解聘。 联席总经理、副总经理、财务总监对总经理负责。 （4）拟订公司的基本管理制 ...

证券代码：603233 证券简称：大参林 公告编号：2026-012 大参林医药集团股份有限公司 第五届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决结果为：8 票同意、0 票反对、0 票弃权。 2、审议通过《关于选举公司第五届董事会专门委员会委员的议案》 根据《上市公司治理准则》《公司章程》及其他有关规定，公司董事会下设 战略与可持续发展委员会、提名委员会、 审计委员会、薪酬与考核委员会等四 个专门委员会，经审议，选举产生公司第五届董事会专门委员会委员及主任委 员，具体如下： 本次董事会无反对或弃权票。 本次董事会议案全部获得通过。 （1）战略与可持续发展委员会由柯云峰先生、柯舟、柯国强、柯拓基、杨 小强等五位董事组成，其中柯云峰先生为主任委员； 重要内容提示： 一、董事会会议召开情况 大参林医药集团股份有限公司（以下简称"公司"）第五届董事会第一次会 议于 2026 年 3 月 31 日以通讯方式召开，本次会议应到董事 8 人，实到董事 8 人。根据公司《董事会议事规则》，经第五届董事会全体 ...

证券代码：603233 证券简称：大参林 公告编号：2026-013 大参林医药集团股份有限公司（以下简称"公司"）于 2026 年 3 月 30 日召 开 2026 年第一次临时股东会，会议选举产生了公司第五届董事会非独立董事 4 名、独立董事 3 名，与经公司 2026 年第一次职工代表大会选举出来的职工代表 董事共同组成公司第五届董事会，任期自股东会通过之日起三年。2026 年 3 月 31 日，公司召开第五届董事会第一次会议，选举产生公司第五届董事会董事长、 各专门委员会委员，并聘任了高级管理人员和证券事务代表。现将具体情况公告 如下： 一、公司第五届董事会组成情况 （1）第五届董事会成员 1、非独立董事：柯云峰（董事长）、柯拓基、谭群飞、柯舟 2、职工代表董事：柯国强 3、独立董事：刘国常、杨小强、龚凯颂 大参林医药集团股份有限公司 关于董事会完成换届选举暨选举公司董事长、董事会专门委员会 委员并聘任公司高级管理人员及证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、公司聘任高级管理人员、证券事 ...

证券代码：603233 证券简称：大参林 公告编号：2026-011 大参林医药集团股份有限公司 2026年第一次临时股东会决议公告 审议结果：通过 表决情况： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 193 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 878,377,237 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 77.1285 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，经过半数董事推举，由董事柯国强主持本次股 东会。会议采取现场投票及网络投票方式召开并表决。会议的召集和召开符合《公 司法》《上市公司股东会规则》和《公司章程》等有关规定。 (一) 股东会召开的时间：2026 年 3 月 30 日 (二) 股东会召开的地点：广州市荔湾区龙溪大道 41 ...

北京市金杜（广州）律师事务所 关于大参林医药集团股份有限公司 2026 年第一次临时股东会的法律意见书 致：大参林医药集团股份有限公司 北京市金杜（广州）律师事务所（以下简称本所）接受大参林医药集团股份有 限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境 内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中 国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、规章和规范性文件 和现行有效的公司章程有关规定，指派律师出席了公司于 2026 年 3 月 30 日召开 的 2026 年第一次临时股东会（以下简称本次股东会），并就本次股东会相关事项 出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 5． 出席现场会议的股东的到会登记记录及凭证资料； 1． 经公司 2025 年第三次临时股东会审议通过的《大参林医药集团股份有限 公司章程》（以下简称《公司章程》）； 2． 公司 2026 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [1] Core Insights - The pharmaceutical sector has shown resilience, with the innovative drug segment leading a rebound, driven by positive industry dynamics and market sentiment [7][10] - The report emphasizes the potential for continued growth in innovative drugs, supported by favorable government policies and strong performance in recent financial disclosures from biotech and biopharma companies [7][10] - The long-term care insurance (LTCI) policy in China is expected to accelerate the development of the elderly care industry, drawing parallels with Japan's successful model [10][23] Summary by Sections 1. Long-term Care Insurance and Elderly Care Industry - The Chinese government aims to establish a long-term care insurance system within three years, initially covering employees, retirees, and gradually including unemployed rural residents [10] - The LTCI system is designed to alleviate the financial burden on families and improve care for the elderly, with a focus on home and community care [10][23] - Investment opportunities in the elderly care sector include home medical devices, rehabilitation equipment, and elderly care institutions [23] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index increased by 1.56% during the week of March 23-27, outperforming the ChiNext and CSI 300 indices [24] - The overall trading volume for pharmaceuticals was 449.11 billion yuan, accounting for 4.28% of the total market, below the historical average of 7.06% [46] - The report highlights the strong performance of innovative drugs, with companies like Meinuohua and Wanbangde leading the gains [49] 3. Investment Recommendations - The report suggests focusing on companies involved in the overseas big pharma BD 2.0 phase, such as Kelun Pharmaceutical and Xinlitai, as well as small and mid-cap biotech firms with innovative technologies [7][23] - It also recommends monitoring the supply chain and technology sectors, including CROs and CDMOs, as they are expected to benefit from ongoing industry trends [7][23]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a decline of 2.77% in the biopharmaceutical sector, while the total A-share market fell by 3.42% [1][35] - Cardiovascular diseases remain the leading cause of death globally, with significant advancements in drug development targeting inflammation pathways, particularly NLRP3, IL-1, and IL-6 [2][33] - The report highlights the importance of addressing "residual risk" in cardiovascular treatment beyond traditional lipid-lowering therapies [33] Summary by Sections Market Performance - The overall A-share market declined by 3.42%, with the Shanghai Composite Index down 2.19% and the ChiNext Index up 1.26% [1][35] - The biopharmaceutical sector's price-to-earnings (P/E) ratio stands at 35.19x, which is at the 77.27th percentile of its historical valuation over the past five years [1][40] Drug Development Insights - The first tier of drug development focuses on apoB/LDL-C, with established treatment paradigms including statins and PCSK9 inhibitors [2][15] - The second tier involves Lp(a) and its associated genetic risks, with several candidates in late-stage clinical trials [2][15] - The third tier emphasizes the NLRP3→IL-1→IL-6→CRP pathway, which is gaining recognition for its clinical relevance in cardiovascular disease [2][33] Company Earnings Forecasts and Ratings - Major companies in the sector, such as Mindray Medical (P/E 17.6x), United Imaging (P/E 74.4x), and WuXi AppTec (P/E 29.2x), are rated as "Outperform" [4] - The report provides detailed earnings forecasts for these companies, indicating expected growth in net profits over the next few years [4] Recommended Stocks - Mindray Medical is highlighted for its strong R&D and sales capabilities, benefiting from domestic healthcare infrastructure and international expansion [44] - WuXi AppTec is noted for its comprehensive service capabilities in drug development, poised to benefit from the global outsourcing market [44] - Other recommended companies include United Imaging, New Industries, and Yuyue Medical, each with unique strengths in their respective fields [44][45]

Investment Rating - The report suggests a positive investment outlook for the innovative drug sector, highlighting potential opportunities due to upcoming clinical data and successful overseas clinical progress of pipelines [2][4]. Core Insights - The chemical products sector is experiencing significant price increases due to rising international oil prices and high overseas energy costs, particularly affecting solvent products which are difficult to stockpile [1][10]. - The raw material pharmaceutical products are expected to see price increases as upstream raw material costs rise, with downstream clients maintaining low inventory levels since April 2023, indicating a potential for sustained price increases and profit elasticity [1][10]. - The report emphasizes the importance of the PI3K/AKT/mTOR signaling pathway in cancer treatment, with renewed focus on PI3K inhibitors, particularly following Novartis's acquisition of Synnovation Therapeutics' PI3Kα inhibitor SNV4818 [34][35][36]. Summary by Sections Raw Materials - The report notes that the pharmaceutical raw material sector is poised for price increases due to rising upstream costs and low inventory levels among clients, which could lead to sustained profitability [1][10]. Pharmaceuticals - Novartis announced a $2 billion upfront payment and up to $1 billion in milestone payments to acquire Synnovation Therapeutics' PI3Kα inhibitor SNV4818, indicating a strategic focus on differentiated therapies in the HR+/HER2- breast cancer market [2][34]. Medical Devices - Innovative products in the medical device sector are expanding into international markets, with companies like MicroPort receiving CE certification for pediatric applications of their surgical robots, enhancing their global brand presence [3][11]. Biologics - The report highlights the promising results of the oral GLP-1 Aleniglipron, which showed significant weight loss in clinical trials, suggesting a shift towards oral formulations that improve patient compliance and reduce logistics costs [3][12]. Traditional Chinese Medicine - The report suggests monitoring undervalued high-dividend assets within the traditional Chinese medicine sector as companies begin to release their performance results [3][12]. Healthcare Services and Consumer Healthcare - The report discusses the upcoming release of the DRG/DIP 3.0 version by the National Healthcare Security Administration, expected to be published around July 2023, which will provide insights into the evolving healthcare payment landscape [3][12]. Investment Recommendations - The report recommends focusing on core sectors such as small nucleic acids, bispecific antibodies, and ADCs, while also identifying opportunities during earnings forecast windows and major clinical data release events [2][4].

2026 年第一次临时股东会会议材料 大参林医药集团股份有限公司 2026 年第一次临时股东会 会议材料 二○二六年三月 2026 年第一次临时股东会会议材料 2026 年第一次临时股东会会议材料 目 录 | 2026 | 年第一次临时股东会会议议程 | 1 | | --- | --- | --- | | 2026 | 年第一次临时股东会会议须知 | 3 | | 2026 | 年第一次临时股东会会议议案 | 4 | | 议案一： | 关于修订《公司章程》及附件的议案 | 4 | | 议案二： | 关于控股子公司天宸健康业务延展至商业保险及专业药房的议案 | 7 | | 议案三： | 关于选举公司第五届董事会非独立董事的议案 | 12 | | 议案四： | 关于选举公司第五届董事会独立董事的议案 | 14 | 大参林医药集团股份有限公司 2026 年第一次临时股东会会议议程 会议表决方式：现场投票与网络投票相结合的方式 会议时间：2026 年 3 月 30 日上午 10 点 网络投票：2026 年 3 月 30 日 网络投票起止时间：采用上海证券交易所网络投票系统，通过交易系统投票 平台的投票时间为股东会召开当 ...

Core Insights - The report emphasizes the investment opportunities in the innovative drug industry chain and undervalued sectors within the pharmaceutical and biotechnology industry [1] - The investment rating is maintained at "Outperform the Market" [2] Group 1: Innovative Drug Development - Continuous progress in clinical development of innovative drugs is noted, with recent excellent clinical data from domestic innovative drugs presented at academic conferences, suggesting a focus on major academic meetings like ASCO in Q2 [4] - The trend of domestic innovative drugs expanding internationally continues, with multiple cooperation agreements indicating the recognition of China's R&D capabilities by multinational pharmaceutical companies [4] Group 2: CXO Industry Investment Opportunities - The CXO sector is identified as the strongest investment theme in the pharmaceutical sector, driven by improved international financing and a robust domestic innovative drug R&D environment [4] - Recommendations include companies such as WuXi AppTec, WuXi Biologics, and Kelun Pharmaceutical, which are expected to benefit from the growing demand in preclinical and clinical stages [4] Group 3: Home Medical Devices and Chain Pharmacies - The home medical device sector is projected to experience strong growth due to aging demographics and increased demand for popular products, with companies like Yuyue Medical and Sanofi Biologics highlighted for their strong positioning [4] - The retail pharmacy sector is expected to consolidate, with leading chain pharmacies like Yifeng Pharmacy and Dazhong Pharmacy likely to gain market share through effective supply chain management and acquisition capabilities [4] Group 4: Surgical Robotics Investment Opportunities - The National Healthcare Security Administration has introduced guidelines for pricing surgical and treatment assistance services, which may enhance the clinical application of intelligent innovative products [4] - Companies like MicroPort and Tianzhihang are noted for their advancements in surgical robotics and international market expansion [4] Group 5: Investment Portfolio - The investment portfolio includes A-shares such as Mindray Medical, United Imaging, and Aier Eye Hospital, as well as H-shares like CanSino Biologics and Hutchison China MediTech [4] Group 6: Industry Performance and Data Tracking - The pharmaceutical manufacturing industry reported a revenue of 24,870 billion yuan in 2025, with a slight decline of 1.2% year-on-year, while total profits increased by 2.7% to 3,490 billion yuan [8] - The retail sales of pharmaceuticals reached 7,294 billion yuan, reflecting a growth of 1.8% year-on-year [8] Group 7: Monthly Performance Review - The pharmaceutical sector experienced a slight decline of 0.18% in February, underperforming against the CSI 300 index [9] - The report indicates that the overall valuation of the pharmaceutical sector is relatively high, with a current PE (TTM) of 37.20, placing it in the 80.66% historical percentile [15]